Bacopa monnieri

Bacopa is a clear case where the answer depends on the outcome and the time frame. The positive findings come from trials of daily use over about 12 weeks, mostly on memory tests [2][3]; single doses and attention measures look different [3][11]. Our evidence grading method explains what each grade requires.

Does bacopa improve memory?

For recall of newly learned material after about 12 weeks of daily use, several trials say yes, but not all [2][3]. A systematic review of six randomized controlled trials (trials in which participants are assigned by chance to bacopa or a comparison), all lasting 12 weeks, in adults without significant cognitive impairment found that bacopa improved performance on 9 of 17 tests of memory free recall, with little evidence of benefit in other cognitive areas [2]. The trials used three different extracts at 300-450 mg a day [2].

A 2026 network meta-analysis, which compares treatments both directly and indirectly across trials, pooled 29 randomized trials with 2,107 healthy adults [3]. For delayed memory, low-dose bacopa (300 to under 600 mg a day) outperformed both placebo and low-dose ginkgo [3]. The authors caution that the lack of direct comparisons may limit the strength of this evidence [3].

Individual trials point the same way. All four were double-blind and placebo-controlled: neither participants nor researchers knew who was taking bacopa, and the comparison group took a dummy pill.

• In a randomized trial of 76 healthy adults aged 40-65, three months of bacopa had a significant effect on a test of retaining new information, while the rate of learning was unaffected, which the authors read as a slower rate of forgetting [5].
• In a randomized trial of 98 healthy adults over 55 (81 completed), a branded extract (BacoMind) at 300 mg a day for 12 weeks improved verbal learning, memory acquisition and delayed recall on the Rey Auditory Verbal Learning Test compared with placebo [6].
• In a randomized trial of 54 healthy adults aged 65 or older, 300 mg a day for 12 weeks improved delayed word recall compared with placebo, in a trial funded by the US National Institutes of Health for which MediHerb supplied the tablets free and whose co-author chairs MediHerb [7].
• In healthy adults, a 12-week trial with random allocation to bacopa or placebo found improved learning rate and memory consolidation compared with placebo [4]. A 2015 erratum corrected the capsule content reported in this paper; the authors said they had relied on incorrect information supplied by the manufacturer [4].

Evidence is mixed, though. In 72 healthy adults aged 35-60 in Bangalore, 450 mg a day for 12 weeks produced no significant differences from placebo on any cognitive measure, in a trial supported by Hindustan Unilever whose authors included three Unilever employees [9]. In a randomized, double-blind, placebo-controlled trial of 101 adults aged 40-70 with self-reported memory and attention problems, a branded extract (Bacumen) at 300 mg a day for 12 weeks did not improve verbal learning compared with placebo, based on the 87 who completed the study, in a trial funded by US Pharma Lab [10]. Its lead author is managing director of Clinical Research Australia, a contract research organization that has received research funding from nutraceutical companies [10]. The authors of the Unilever-supported trial suggest that inconsistent results in the literature may be linked to methodological issues [9]. The proposed grade carries the "short-term only" modifier because the trials lasted about 12 weeks [2].

Working memory has its own mixed record. In the network meta-analysis, doses of 600 mg a day or more improved working memory compared with placebo (standardized mean difference 2.03, 95% CI 1.28-2.78), though the authors caution that the lack of direct comparisons may limit the strength of this evidence [3]. A randomized, double-blind, placebo-controlled 90-day trial of KeenMind in healthy adults (107 recruited, 62 completed) found better spatial working memory accuracy [8], and a randomized, double-blind, placebo-controlled 12-week trial in 60 healthy older adults found improved working memory [14]. The 2025 Bacumen trial found no difference in working memory, in a trial funded by US Pharma Lab [10]. Working memory is not graded on this page yet.

Does bacopa improve attention and processing speed?

Evidence is mixed, and the two pooled analyses disagree [1][3]. A 2014 meta-analysis of nine randomized placebo-controlled trials of standardized extracts taken for 12 weeks or more (518 participants across the trials, 437 of them in the pooled analysis) found a shorter completion time on the Trail B test (-17.9 ms; 95% CI -24.6 to -11.2), and concluded bacopa may improve speed of attention [1]. The trials included both healthy and impaired participants, and the abstract gives no estimate for healthy adults alone [1]. Its authors rated the overall quality of the included trials as low risk of bias [1]. Its reported choice reaction time result is internally inconsistent in the abstract, so we do not cite it.

The 2026 network meta-analysis, limited to healthy adults and including more trials, found no significant differences in sustained attention, selective attention or processing speed [3]. Single trials also split: one found faster visual information processing after 12 weeks [4], while attention was unaffected in another [5], and the 2025 Bacumen trial, funded by US Pharma Lab, found no difference in attention [10]. Because the larger and more recent analysis, limited to healthy adults, is null, we rate this evidence as mixed rather than as a benefit.

Does a single dose of bacopa do anything?

The evidence for single doses is thin and inconsistent. In a randomized trial of 38 healthy adults, 300 mg of bacopa produced no significant changes on any test 2 hours after dosing compared with placebo [11]. In a double-blind, placebo-controlled crossover trial of 24 healthy volunteers, in which each person took every treatment, 320 mg improved performance on some repetitions of a demanding test battery, while 640 mg was also tested; this trial was co-funded by the company Soho Flordis International, according to the publisher's funder record [12]. In a double-blind, placebo-controlled crossover study of 17 healthy volunteers, both 320 mg and 640 mg improved scores on two tasks, letter search and the Stroop test, 1 and 2 hours after dosing [13].

All three trials were led from Swinburne University of Technology [11][13], including the one co-funded by Soho Flordis International [12], which is why the proposed grade carries the "single research group" modifier, and the authors of the third study say the effects need to be replicated in a larger sample [13].

Does bacopa reduce stress?

Evidence is mixed and comes from questionnaires, so the proposed grade carries the "subjective outcome only" modifier. A 12-week trial in healthy adults found lower state anxiety, a measure of how anxious someone feels at the moment, compared with placebo [4]. In adults aged 65 or older, combined state and trait anxiety scores fell with bacopa and rose with placebo, in a trial for which MediHerb supplied the tablets [7]. In the 2025 trial in adults aged 40-70 with self-reported memory and attention problems, funded by US Pharma Lab, bacopa produced greater reductions in self-reported stress reactivity, a secondary outcome, among the 87 of 101 participants who completed it [10].

Other trials found no such effect. Anxiety levels were unaffected in the trial of adults aged 40-65 [5], and the Unilever-supported trial found only a trend toward lower state anxiety [9]. In a small single-dose study, there were some positive mood effects and lower cortisol, a stress hormone [13], while another single-dose trial found no effect on task-induced stress ratings, in a trial co-funded by Soho Flordis International [12].

What the evidence does not show

The 2012 systematic review found little evidence that bacopa improves cognitive areas other than memory free recall [2], and the 2026 network meta-analysis found no statistically significant differences in attention or processing speed [3]. As of November 11, 2026 we found no human pharmacokinetic studies of Bacopa monnieri (PubMed and Europe PMC searches), so there is no measured onset or half-life to report. The memory trials ran for about 12 weeks [2], so they do not show what happens with longer use.

Onset and half-life are unknown (see above). In the trials, memory outcomes were measured after about 12 weeks [2], and one trial found the largest effects at 12 weeks rather than at 5 weeks [4]. In the single-dose studies, testing took place 1-2 hours after dosing [11][13].

Ethanol extracts were the form most commonly used in studies, according to a 2025 review [15]. Branded extracts tested include BacoMind [6], KeenMind [8] and Bacumen, in a trial funded by US Pharma Lab [10].

In the 12-week trial in healthy adults over 55, bacopa caused more increased stool frequency, abdominal cramps and nausea than placebo [6]. In adults aged 65 or older, 300 mg a day was well tolerated, with adverse events in 9 people on bacopa and 10 on placebo, mainly stomach upset, in a trial for which MediHerb supplied the tablets [7]. In the 2025 trial funded by US Pharma Lab, self-reported adverse reactions were more frequent with bacopa than placebo (p = 0.024), mostly digestive complaints and headaches, with no serious adverse reactions [10].

A 2025 review names gastrointestinal disorders as the most common side effects [15]. The same review also reports side effects when bacopa was taken with two antidepressants, including a myocardial infarction (heart attack) with moclobemide [15], and notes that research on use in pregnant and breastfeeding women is lacking [15].

LiverTox, an NIH liver injury database, says bacopa has not been linked to liver enzyme elevations or to clinically apparent acute liver injury, and rates it an unlikely cause of such injury (likelihood score E) [24]. It describes side effects as minor and usually short-lived, such as abdominal pain, nausea, diarrhea and headache [24]. A 2023 letter reports a case of necrotizing myopathy, a serious muscle condition, following exposure to a bacopa supplement [19]. We could not read the letter, so its details are not verified as of November 12, 2026.

Product quality is a separate concern. In an analysis of wild bacopa collected near Indian cities, most samples exceeded threshold limits for cadmium, lead, copper and zinc for use as raw medicinal plant material [18]. Those were plant samples, not finished supplements, and the authors say wild-collected bacopa needs testing for trace metals before it is used in herbal formulations [18].

In laboratory tests on recombinant human CYP enzymes, bacopa extract inhibited CYP2C19, CYP2C9, CYP1A2 and CYP3A4, enzymes that break down many medicines, while purified bacosides had little effect [16]. The authors concluded the extract could contribute to herb-drug interactions when taken by mouth with medicines broken down by those enzymes [16]. A 2025 review reports an interaction between bacopa extract and amitriptyline [15]. The same review reports back pain and excessive sweating when bacopa extract was taken with agomelatine, an antidepressant broken down by CYP1A2, and a myocardial infarction when bacopa was combined with moclobemide, an antidepressant broken down by CYP2C19 [15]. The review gives no study details for these reports, so they do not show that bacopa caused the events. The review also advises attention to medicines that affect thyroxine (T4) levels, based on the mouse study described below [15].

One case report describes a woman taking cevimeline who developed sweating, malaise, nausea and a fast heart rate after taking a supplement containing bacopa and phosphatidylserine the previous night; she improved with hydration and after stopping the supplement [17]. A single case cannot show cause.

These sources describe what has been reported, not what is right for any individual. If you take any of these medicines, talk to your doctor or pharmacist before combining them with bacopa.